Compound: PIRFENIDONE
SMILES: O=c1n(-c2ccccc2)cc(C)cc1
InChIKey: ISWRGOKTTBVCFA-UHFFFAOYSA-N
Synonyms: PIRFENIDONE, 53179-13-8, Esbriet, Pirespa, AMR-69, Pirfenidona, Pirfenidonum, 2(1H)-Pyridinone, 5-methyl-1-phenyl-, 5-Methyl-1-phenyl-2(1H)-pyridone, 5-methyl-1-phenylpyridin-2-one, AMR 69, D7NLD2JX7U, NSC-748456, DTXSID4045183, DTXCID2025183, CHEBI:32016, ESBRIET COMPONENT PIRFENIDONE, 5-METHYL-1-PHENYL-1,2-DIHYDROPYRIDIN-2-ONE, RefChem:58560, L04AX05, 5-methyl-1-phenylpyridin-2(1H)-one, 5-methyl-1-phenyl-2(1H)-pyridinone, 5-Methyl-1-phenyl-2-(1H)-pyridone, Deskar, MFCD00866047, 5-Methyl-1-phenyl-2-pyridone, 5-methyl-1-phenyl-2-pyridinone, NCGC00015806-03, 5-Methyl-N-phenyl-2-1H-pyridone [Pirfenidone], Pirfenidone [USAN:INN], Pirfenidonum [INN-Latin], Pirfenidona [INN-Spanish], 5-Methyl-1-phenyl-1H-pyridin-2-one, CAS-53179-13-8, Pirfenidone; 5-Methyl-N-phenyl-2-1H-pyridone, SR-01000076061, UNII-D7NLD2JX7U, S-7701, BRN 1526549, Pirfenidone (JAN/USAN/INN), Pirfenidone CRS, 5-methyl-1-phenyl-pyridin-2-one, Esbriet (TN), KS-5041, 2(1H)-Pyridone, 5-methyl-1-phenyl-, Pirfenidone (Standard), Tocris-1093, Pirfenidone(AMR69)?, PIRFENIDONE [MI], Lopac-P-2116, PIRFENIDONE [INN], PIRFENIDONE [JAN], F-647, PIRFENIDONE [USAN], P 2116, PIRFENIDONE [VANDF], SCHEMBL4708, PIRFENIDONE [MART.], Lopac0_000907, PIRFENIDONE [WHO-DD], 5-21-07-00197 (Beilstein Handbook Reference), MLS000860042, PIRFENIDONE [EMA EPAR], GTPL7532, orb1305557, orb3025184, CHEMBL1256391, Pirfenidone - Bio-X trade mark, 1-phenyl-5-methyl-2-pyridinone, HSDB 8340, HY-B0673R, Pirfenidone, >=97% (HPLC), PIRFENIDONE [ORANGE BOOK], Bio1_000397, Bio1_000886, Bio1_001375, HMS2234G24, HMS3262F16, HMS3267I06, HMS3372A08, HMS3412G13, HMS3651P08, HMS3676G13, HMS5081J21, PIRFENIDONE [EP MONOGRAPH], HY-B0673, Tox21 110225, Tox21_110225, Tox21_500907, 5-methyl-1-phenyl-2(1H)pyridinone, BDBM50005201, EBC-17030, NSC748456, s2907, AKOS006273697, Tox21_110225_1, AB07515, AC-6797, CCG-204989, DB04951, FM25909, LP00907, NSC 748456, SDCCGSBI-0050882.P002, NCGC00015806-01, NCGC00015806-02, NCGC00015806-04, NCGC00015806-05, NCGC00015806-06, NCGC00015806-17, NCGC00024992-01, NCGC00024992-02, NCGC00024992-03, NCGC00261592-01, 5-METHYL-N-PHENYL-2-1H-PYRIDONE, BM164275, SMR000326900, SY034783, EU-0100907, NS00001642, P1871, SW220156-1, D01583, EN300-7366392, F079427, Q2060696, SR-01000076061-1, SR-01000076061-3, 5-Methyl-N-phenyl-2-1H-pyridone-d5(pirfenidone-d5), BRD-K96862998-001-03-1, BRD-K96862998-001-09-8, BRD-K96862998-001-14-8, BRD-K96862998-001-15-5, Pirfenidone, European Pharmacopoeia (EP) Reference Standard
Theoretical properties:
molecular_formula: C12H11NO
molecular_weight: 185.22 g/mol
exact_mass: 185.084063974 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 1
rotatable_bond_count: 1
heavy_atom_count: 14
topological_polar_surface_area: 20.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: White solid from hot water
color: White solid from hot water
solubility: Solubule in methanol
Descriptions:
pubchem: Pirfenidone is a pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis. It has a role as an antifibrotic agent, a non-steroidal anti-inflammatory drug, a non-narcotic analgesic and an antipyretic.
chebi: A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis.
chembl: PIRFENIDONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Pirfenidone, sold under the brand name Esbriet among others, is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II.
It was first approved in Japan for the treatment of people with idiopathic pulmonary fibrosis after clinical trials in 2008. It was approved for use in the European Union in 2011, in Canada in 2012, and in the United States in October 2014.
It is available as a generic medication.